BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 6, 2025
See today's BioWorld Asia
Home
» US FDA approves six NMEs in July; Kalvista, PTC, Regeneron rise
To read the full story,
subscribe
or
sign in
.
Biopharma regulatory actions and approvals July 2025
US FDA approves six NMEs in July; Kalvista, PTC, Regeneron rise
Aug. 26, 2025
By
Amanda Lanier
No Comments
The U.S. FDA approved 17 drugs in July, down from 23 in June, bringing the year-to-date total to 125. Through July, 2025 remains the third-highest count in
BioWorld’s
records, trailing 135 approvals in 2024 and 126 in 2020.
BioWorld Asia
Analysis and data insight
Regulatory
FDA
NME